Vanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $51.91 million for the quarter.

Vanda Pharmaceuticals Stock Down 2.3 %

Shares of NASDAQ VNDA opened at $4.31 on Tuesday. The firm has a market capitalization of $251.32 million, a P/E ratio of -15.39 and a beta of 0.74. The stock’s 50-day simple moving average is $4.70 and its two-hundred day simple moving average is $4.95. Vanda Pharmaceuticals has a twelve month low of $3.46 and a twelve month high of $6.75.

Insider Activity

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the transaction, the director now owns 44,857 shares in the company, valued at $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research report on Tuesday, January 28th. They set a “hold” rating for the company. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, January 28th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.